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government and private health insurers. Results: The total revenue and costs of 
PHI companies were 2.3 billion TL and 1.7 billion TL and per capita revenue and cost 
of private health insurance companies were 822 TL and 631 TL in 2013, respectively. 
The gross profit of all PHI companies was 0.6 billion or 26%. The SSI’s revenue and 
cost for health insurance were 53 billion and 49.9 billion TL, per capita revenue and 
cost of health insurance were 691 TL and 650 TL in 2013, respectively. The gross profit 
of SSI health insurance was 4.1 billion and 5%. ConClusions: The SSI has become 
the monopsonic payer in the Turkish health system with mandatory health insur-
ance premium collection from all Turkish citizen. The SSI determines its revenues 
and costs. Based on this power, the SSI has 4.1 billion gross revenue in total. This 
shows the success of SSI’s management while covering the whole population for a 
very comprehensive health care package. However, the SSI’s per capita revenue is 
lower and its cost is higher than private sector averages.
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objeCtives: To assess current status of HTA implementation in Central-Eastern 
European (CEE) countries and to identify long-term objectives considering country 
specific aspects and regional commonalities. Methods: An HTA implementation 
survey was designed to identify, present and discuss HTA roadmaps in CEE coun-
tries. The survey was conducted among participants at the Fifth Adriatic Congress 
of Pharmacoeconomics and Outcomes Research (Sibenik) and at the Pilot ISPOR HTA 
Training for CEE countries in June 2015 (Zagreb). Opinion of respondents on cur-
rent and preferred future status of HTA implementation in their own country were 
described related to capacity building, HTA financing, process and organisational 
structure for HTA, standardization of HTA methodology, use of local data, scope of 
mandatory HTA, and decision criteria. Results: 41 participants (78% public sector 
employees) from 11 CEE countries filled in the survey. 75% of respondents would 
prefer postgraduate training for HTA capacity building, however, only 15% reported 
a currently implemented program and 33% reported no regular HTA trainings in 
their countries. Participants would increase public funding on HTA research (6% 
current vs. 65% preferred) and on critical appraisal of HTA submissions (15% cur-
rent vs. 64% preferred). 73% of participants would prefer establishment of public 
HTA agency with academic support, however only 10% reported the existence of 
such agency. 92% of respondents would mandate the use of local data with need for 
assessing the transferability of international evidence (vs. 34% currently). 86% would 
prefer development of patient registries and access to data in payers’ databases (vs. 
11% currently). ConClusions: Our results must be viewed as an initial step in a 
multi-stakeholder dialogue on HTA implementation. Each CEE country should 
develop their own HTA roadmap, as such roadmaps are not fully transferable with-
out taking into account country size, GDP per capita, major social values, public 
health priorities and fragmentation of health care financing.
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objeCtives: The Italian Medicine Agency (AIFA) has recently introduced con-
ditional reimbursement schemes to promote access to oncology therapies, and 
reduce the risk of funding treatments with lower effectiveness than observed 
in clinical trials. These schemes are designed to be terminated after few years 
once treatment value is reassessed based on available real world data. Payment 
by Results (PbR) is frequently applied; manufacturers would be asked to pay back 
the treatment costs for patients receiving the new therapy if progression occurs 
before a pre-specified threshold. Methods: A simulation tool was built to assess 
the impact of the implementing PbR scheme and quantify the resulting increase 
in clinical value of a new treatment. Progression Free Survival (PFS) curves have 
been simulated using parametric distributions and hazard ratios to generate vari-
ous scenarios that may be observed in clinical trials. Patients receiving the new 
treatment and experiencing a recurrence before the PbR threshold were censored 
within the survival curves. PbR was also investigated considering Bevacizumab 
(Bev) in cervical cancer (CC). Results: The improvement in mPFS resulting of PbR 
was significant and meaningful in every scenario generated. The magnitude of the 
benefit depended mostly of the shape of parametric distribution. When applied 
to Bev in CC, a 3-month PbR scheme resulted in an improvement of Bev mPFS 
from 8.3 to 10.0 months (leading to a 4.1 months median incremental benefit over 
chemotherapy). ConClusions: Based on this simulation study, and the underlying 
assumptions, the patient access scheme proposed by AIFA would, in most scenarios, 
be associated with an increase in median incremental benefit for the patients, fewer 
costs for the payers and therefore better value for money.
PHP143
Patient aCCess sCHemes WitHin tHe uk: a retrosPeCtiVe analysis
Maguire PT, Gibson E
Wickenstones, Goring Heath, UK
objeCtives: In recent years there has been an increasing strain on healthcare 
budgets. As a result, policymakers have adapted the framework for evaluating new 
medicines so manufacturers need to demonstrate additional benefit and value for 
money to achieve reimbursement. One of the key policy tools available are man-
aged entry agreements. In the UK these are assessed as patient access schemes 
(PAS) which have been successfully used to obtain cost effectiveness since 2007. 
information; collect pricing and reimbursement rules from each country; validate 
pricing and reimbursement rules monthly. The system was piloted by 3 affiliates 
(4 users). Results: The web-based system was introduced in March 2013, and 
has 246 users. The number of pricing applications/year increased from 124 (2012) 
with the Excel-based system to 455 (2013) and 312 (2014) with the web-based sys-
tem. The mean time for price approval/rejection decreased from approximately 
40 days (old system) to 6.5 days (new system). The mean time to respond to a 
pricing request decreased from 4 days (old system) to 0 days (i.e. information is 
available on new system). The estimated time needed to create monthly updates 
decreased from 1–2 days to 1–2 minutes (for simple reports). Further, the system 
enabled analyses to be performed internally, which would previously have been 
outsourced. ConClusions: The e-pricing system has improved the efficiency, 
reliability, compliance, transparency and ease of access to multinational drug 
pricing and approval information.
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objeCtives: Biosimilar discount expectations are often quoted at 20-30% of the 
originator’s price, but this benchmark was hugely underrated during recent tender 
bids in Norway. Orion Oyj astonished many when it decreased the price of its inf-
liximab biosimilar by 72%, a 69% discount vs. the originator. In our study, we aim 
to evaluate the risk of similar discounting levels occurring in the EU5 markets for 
IV biosimilars in the hospital setting. Methods: We evaluated IV biosimilar and 
originator biologic pricing, access and procurement policies across the EU5 markets 
to develop hypotheses on extreme biosimilar discounting risk levels. Results: All 
EU5 markets require biosimilars to launch at a discounted net price to attain reim-
bursement, and net pricing is negotiated at several levels. Regions and hospital pur-
chasing groups are anticipated to attain the greatest discounts or rebates, which will 
likely be greatest during exclusive or single-biosimilar source tenders that can shape 
biosimilar share. Payers using direct purchasing at the individual hospital level and 
those which leverage several non-price focused biosimilar adoption policies are 
expected to attain lower biosimilar discounts, due to reduced bargaining power or 
a lower dependence on cost savings to shape biosimilar uptake. ConClusions: We 
hypothesise that Spain, the UK and regions in Italy with exclusive tenders are at the 
greatest relative risk of repeating similar extreme discounting behaviours. France, 
Germany and regions in Italy not holding exclusive tenders are anticipated to realise 
lower biosimilar discounts. Furthermore, the lowest discounts are anticipated in 
non-hospital IV settings in Germany, where non-price focused biosimilar policies 
are expected to encourage adoption in treatment naïve patients, and exclusive 
rebate contracts with the originator will slow down switching of stable patients 
and biosimilar net price reductions.
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objeCtives: Activity-based financing (T2A) reforms in France in 2004 led to the 
creation of a list of high-cost drugs reimbursed outside the hospital budget, the 
“liste-en-sus”. In 2013, this spending was over 2.8 billion Euro, with 7.5% growth. 
Consequently, the French government has adopted multiple measures to control 
spending on “liste-en-sus” drugs. The most common measure taken is removal 
from the list. Patients and manufacturers have claimed that without such financ-
ing, removed drugs would not be prescribed, effectively denying access to certain 
products with marketing authorisation. We investigated the validity of this claim 
and the impact on healthcare spending of “liste-en-sus” removal. Methods: Using 
government ATIH data on “liste-en-sus” products and IMS MIDAS prescribing data, 
we identified 64 brands (48 molecules) removed from the list between 2007 and 2015. 
We then measured prescribing before and after removal and categorized the removal 
decisions. Results: Reasons for removal from the “liste-en-sus” can be categorised 
as follows: Price cut following launch of a generic or a biosimilar: 36 (20 molecules) 
Marketing authorization withdrawn: 3 Prescribing shift to retail setting: 4 Insufficient 
clinical value: 21 (of which 8 are announced for 2015/16). IMS MIDAS data analysis of 
the 13 products removed for insufficient clinical value between 2006-2013 shows that 
prescribing of half of these products was maintained or even increased, suggesting 
that removal did not deprive patients of authorized medicines. Sales of the remaining 
products fell after removal, as suitable alternatives were available for patients. For 
drug manufacturers, removal typically reduces sales; either through price discounts 
to achieve hospital reimbursement levels, or a fall in prescribing. ConClusions: 
The French “liste-en-sus” is meant to offer temporary funding for innovation, yet the 
number of removals is low. While removal has no negative consequences for patients, 
the real savings from such measures is limited and unlikely to reduce drug spending.
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objeCtives: The Health Transformation Program commenced in2002 by Ministry 
of Health(MoH) in Turkey. Today, Turkey has a well established health system 
mostly dominated by government as healthcare provider and payer. Social Security 
Institution(SSI) is the only government payer covering 99% of the Turkish population. 
There are private health insurance(PHI) companies covering only 3% of the popula-
tion. The aim of the analysis is to compared the profitability of health insurance 
in Turkey. Methods: The most updated data of revenue and cost of PHI data was 
obtained from Turkish Private Insurance Association for years 2009-2013. The official 
revenue and cost of government health insurance data was obtained from SSI for the 
same years. Descriptive analysis were conducted with the revenue and cost data of 
